Travere Therapeutics (TVTX) Financials

$21.41 +0.26 (+1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$21.40 -0.02 (-0.07%)

As of 04:05 PM Eastern

Annual Income Statements for Travere Therapeutics

This table shows Travere Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-111	117	-48	-60	-103	-146	-169	-180	-278	-111	-322
Consolidated Net Income / (Loss)	-111	117	-48	-60	-103	-146	-169	-180	-278	-111	-322
Net Income / (Loss) Continuing Operations	-111	117	-48	-60	-103	-146	-169	-217	-331	-376	-321
Total Pre-Tax Income	-113	105	-58	-58	-102	-146	-189	-217	-331	-376	-321
Total Operating Income	-80	-51	-58	-54	-80	-137	-176	-199	-320	-388	-324
Total Gross Profit	28	98	129	151	159	170	192	128	105	134	225
Total Revenue	28	100	134	155	164	175	198	132	109	145	233
Operating Revenue	28	100	134	155	164	175	198	132	109	145	233
Total Cost of Revenue	0.57	2.19	4.55	3.61	5.53	5.23	6.13	3.82	4.42	11	7.74
Operating Cost of Revenue	0.57	2.19	4.55	3.61	5.53	5.23	6.13	3.82	4.42	11	7.74
Total Operating Expenses	107	148	187	205	239	307	368	327	425	522	549
Selling, General & Admin Expense	60	80	92	101	104	129	136	126	198	266	264
Research & Development Expense	48	50	71	78	124	141	229	201	227	245	283
Restructuring Charge	-	0.00	0.89	3.61	-0.24	-	-	0.00	0.00	11	2.44
Total Other Income / (Expense), net	-34	156	0.67	-4.57	-22	-9.09	-13	-17	-11	12	3.32
Interest Expense	0.00	4.15	0.73	4.42	27	-	0.00	0.00	19	11	11
Interest & Investment Income	-7.44	-7.75	-	3.23	5.50	-8.77	-14	-18	6.28	22	18
Other Income / (Expense), net	-26	168	1.39	-3.38	-0.47	-0.31	1.42	0.23	0.97	1.59	-3.32
Income Tax Expense	-2.46	-12	-9.68	1.37	0.81	-0.02	-19	0.41	0.31	0.22	0.12
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	37	53	265	-0.92
Basic Earnings per Share	($4.43)	$3.49	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)
Weighted Average Basic Shares Outstanding	25.06M	33.56M	37.00M	38.77M	40.43M	42.34M	47.54M	59.83M	63.76M	74.27M	78.89M
Diluted Earnings per Share	($4.43)	$3.17	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)
Weighted Average Diluted Shares Outstanding	25.06M	37.58M	38.29M	38.77M	40.43M	42.34M	47.54M	59.83M	63.76M	74.27M	78.89M
Weighted Average Basic & Diluted Shares Outstanding	25.06M	33.60M	37.10M	38.77M	40.43M	42.34M	47.54M	63.21M	64.74M	76.10M	88.74M

This table shows Travere Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-70	-66	-86	-86	151	-90	-136	-70	-54	-61
Consolidated Net Income / (Loss)	-70	-66	-86	-86	151	-90	-136	-70	-55	-60
Net Income / (Loss) Continuing Operations	-84	-104	-97	-102	-89	-89	-136	-70	-55	-60
Total Pre-Tax Income	-84	-104	-96	-102	-89	-89	-136	-70	-55	-60
Total Operating Income	-83	-106	-97	-104	-93	-94	-139	-68	-56	-61
Total Gross Profit	27	-20	27	31	36	40	40	52	61	72
Total Revenue	28	-21	31	32	37	45	41	54	63	75
Operating Revenue	28	-21	31	32	37	45	41	54	63	75
Total Cost of Revenue	1.11	-0.88	4.15	1.45	1.29	4.56	1.50	2.06	1.63	2.55
Operating Cost of Revenue	1.11	-0.88	4.15	1.45	1.29	4.56	1.50	2.06	1.63	2.55
Total Operating Expenses	110	85	124	135	128	135	179	120	117	133
Selling, General & Admin Expense	52	45	66	68	68	64	64	65	66	70
Research & Development Expense	57	54	58	66	61	60	115	54	52	62
Restructuring Charge	-	-	0.00	0.00	0.00	11	0.26	0.65	0.12	1.40
Total Other Income / (Expense), net	-1.31	1.29	0.88	2.08	3.36	5.71	3.47	-1.86	1.31	0.40
Interest & Investment Income	-0.73	11	0.80	5.13	5.84	10	3.23	4.42	3.57	6.60
Other Income / (Expense), net	-0.59	0.87	0.09	-0.20	0.34	1.37	0.24	-3.50	0.52	-0.58
Income Tax Expense	0.15	0.06	0.08	0.07	0.01	0.07	0.19	0.09	-0.08	-0.07
Net Income / (Loss) Discontinued Operations	14	-	10	16	240	-1.58	-0.10	-0.76	-0.06	0.00
Basic Earnings per Share	($1.09)	($1.03)	($1.27)	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)
Weighted Average Basic Shares Outstanding	64.03M	63.76M	68.17M	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M
Diluted Earnings per Share	($1.09)	($1.03)	($1.27)	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)
Weighted Average Diluted Shares Outstanding	64.03M	63.76M	68.17M	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M
Weighted Average Basic & Diluted Shares Outstanding	64.17M	64.74M	74.61M	75.01M	75.15M	76.10M	76.13M	76.49M	78.05M	88.74M

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	12	20	3.20	58	3.48	-40	22	81	-104	-3.51	1.27
Net Cash From Operating Activities	-46	-1.39	-3.44	7.40	-25	-58	-43	-15	-186	-280	-237
Net Cash From Continuing Operating Activities	-46	-1.39	-3.44	7.40	-25	-58	-43	-76	-261	-325	-230
Net Income / (Loss) Continuing Operations	-111	117	-48	-60	-103	-146	-169	-217	-331	-376	-321
Consolidated Net Income / (Loss)	-111	117	-48	-60	-103	-146	-169	-180	-278	-111	-322
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	37	53	265	-0.92
Depreciation Expense	5.40	13	16	18	19	20	25	13	21	39	44
Amortization Expense	5.79	1.74	1.75	1.99	3.78	9.12	10	13	0.92	-5.74	-2.81
Non-Cash Adjustments To Reconcile Net Income	44	-121	26	31	53	62	130	34	48	44	113
Changes in Operating Assets and Liabilities, net	10	-13	0.93	17	2.53	-3.04	-38	81	0.88	-24	-63
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	-	61	75	45	-7.45
Net Cash From Investing Activities	-37	-81	10	46	-203	20	-61	-138	-33	56	99
Net Cash From Continuing Investing Activities	-37	-81	10	46	-203	20	-61	-138	-33	-152	99
Acquisitions	-32	-40	-11	-13	-34	-15	-113	-19	-28	-42	-36
Purchase of Investments	-11	-199	-184	-102	-331	-224	-215	-547	-385	-444	-126
Sale and/or Maturity of Investments	6.49	9.98	207	162	163	259	273	434	382	335	326
Other Investing Activities, net	-0.09	0.00	0.00	-	-	-	0.00	0.00	-0.79	-0.67	-65
Net Cash From Discontinued Investing Activities	-	-	-	-	-	-	-	0.00	0.00	207	0.00
Net Cash From Financing Activities	95	102	-3.85	5.45	232	-2.08	128	232	118	219	139
Net Cash From Continuing Financing Activities	95	102	-3.85	5.45	232	-2.08	128	238	120	220	139
Repayment of Debt	-32	-47	-1.36	-0.85	-41	-	0.00	0.00	-221	0.00	0.00
Issuance of Debt	85	0.00	0.00	0.66	278	-	0.00	0.00	316	0.00	0.00
Issuance of Common Equity	48	154	6.01	3.65	5.31	1.78	134	227	23	219	137
Other Financing Activities, net	-1.16	4.14	-8.50	1.99	-1.13	-3.85	-5.85	11	2.49	3.24	2.35
Net Cash From Discontinued Financing Activities	-	-	-	-	-	-	-	-6.10	-2.48	-1.38	0.00
Cash Interest Paid	4.08	5.84	2.07	2.07	1.88	7.67	6.90	7.33	10	8.84	8.84
Cash Income Taxes Paid	0.01	9.61	7.93	7.17	0.22	0.66	-3.37	-16	1.00	0.58	0.45

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-28	-90	100	-91	73	-86	-15	-11	4.12	23
Net Cash From Operating Activities	-40	-55	-81	-69	-59	-70	-119	-40	-43	-36
Net Cash From Continuing Operating Activities	-92	-77	-99	-88	-74	-64	-119	-40	-43	-29
Net Income / (Loss) Continuing Operations	-103	-86	-97	-102	-89	-89	-136	-70	-55	-60
Consolidated Net Income / (Loss)	-70	-66	-86	-86	151	-90	-136	-70	-55	-60
Net Income / (Loss) Discontinued Operations	-	20	10	16	240	-1.58	-0.10	-0.76	-0.06	0.00
Depreciation Expense	-0.79	6.31	6.62	11	11	9.49	9.88	10	11	12
Non-Cash Adjustments To Reconcile Net Income	-4.57	6.31	12	9.68	8.23	13	10	80	7.69	15
Changes in Operating Assets and Liabilities, net	17	-5.02	-21	-6.60	-4.90	8.09	-2.95	-61	-6.74	7.40
Net Cash From Discontinued Operating Activities	-	22	18	19	15	-6.10	-0.10	-0.31	0.05	-7.09
Net Cash From Investing Activities	10	-37	-37	-24	133	-17	105	29	46	-80
Net Cash From Continuing Investing Activities	10	-37	-37	-24	-73	-18	105	29	46	-80
Acquisitions	-7.62	-4.17	-27	-3.83	-4.92	-5.51	-6.47	-12	-8.19	-9.64
Purchase of Investments	-95	-84	-103	-122	-156	-63	0.00	-	-	-126
Sale and/or Maturity of Investments	112	52	94	103	88	50	111	106	54	55
Other Investing Activities, net	-	-	-	-	-	-	-	-	-	-0.04
Net Cash From Financing Activities	2.28	0.55	217	2.27	-0.63	0.12	-0.53	0.78	0.05	139
Net Cash From Continuing Financing Activities	4.15	1.16	218	2.53	-0.37	0.38	-0.53	0.78	0.05	139
Issuance of Common Equity	-	1.45	216	2.26	-	0.91	0.00	1.31	-	136
Other Financing Activities, net	4.15	-0.29	1.77	0.27	-0.37	1.58	-0.53	-0.53	0.05	3.36

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	135	512	525	520	709	605	607	777	673	789	594
Total Current Assets	37	302	332	326	496	429	410	583	486	617	417
Cash & Equivalents	18	38	41	99	103	62	85	166	62	58	59
Short-Term Investments	9.56	192	215	201	369	336	277	387	389	509	312
Accounts Receivable	7.96	12	19	14	13	18	16	16	17	21	27
Inventories, net	0.80	2.54	2.83	5.35	5.62	6.08	7.61	7.31	4.52	9.41	6.20
Prepaid Expenses	0.81	2.38	4.83	3.11	4.14	5.02	8.14	6.72	12	19	13
Plant, Property, & Equipment, net	0.67	0.43	2.59	3.23	3.15	2.89	9.42	11	9.05	7.48	5.34
Total Noncurrent Assets	97	210	190	191	210	173	188	183	177	165	172
Intangible Assets	94	162	182	185	187	157	154	148	97	104	104
Other Noncurrent Operating Assets	2.27	1.86	7.36	5.56	7.71	15	33	34	32	60	68
Total Liabilities & Shareholders' Equity	135	512	525	520	709	605	607	777	673	789	594
Total Liabilities	173	212	218	227	391	384	396	475	630	588	535
Total Current Liabilities	108	87	83	86	105	95	93	124	142	178	201
Short-Term Debt	40	-	-	0.00	22	-	17	7.40	-	0.00	69
Accounts Payable	7.12	7.64	7.52	19	6.95	27	12	15	17	42	24
Accrued Expenses	29	26	35	38	50	52	57	75	96	119	86
Current Deferred Revenue	-	-	-	-	-	-	0.00	16	12	7.10	2.82
Other Current Liabilities	31	54	40	29	26	17	6.33	10	10	10	20
Total Noncurrent Liabilities	65	125	134	142	286	288	304	350	488	410	334
Long-Term Debt	43	44	44	45	195	205	215	227	376	377	310
Other Noncurrent Operating Liabilities	22	57	83	96	91	83	88	103	37	33	24
Commitments & Contingencies	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-37	300	308	293	318	221	211	302	43	201	59
Total Preferred & Common Equity	-37	300	308	293	318	221	211	302	43	201	59
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-37	300	308	293	318	221	211	302	43	201	59
Common Stock	141	366	421	472	590	637	798	1,069	1,060	1,328	1,506
Retained Earnings	-179	-65	-113	-178	-270	-416	-586	-766	-1,014	-1,126	-1,447
Accumulated Other Comprehensive Income / (Loss)	4.29	-0.68	-0.49	-1.02	-1.53	0.73	-0.90	-0.56	-2.91	-1.46	-0.08

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	726	808	736	833	664	551	504
Total Current Assets	535	605	542	686	481	369	325
Cash & Equivalents	151	161	71	144	43	32	36
Short-Term Investments	355	400	420	490	398	293	241
Accounts Receivable	13	22	20	15	23	24	25
Inventories, net	7.30	6.71	19	21	4.53	5.98	6.36
Prepaid Expenses	8.55	15	12	16	13	13	16
Plant, Property, & Equipment, net	9.56	9.13	8.57	8.00	6.94	6.58	6.16
Total Noncurrent Assets	182	194	186	139	176	176	174
Intangible Assets	149	163	154	107	101	105	104
Other Noncurrent Operating Assets	32	31	31	32	74	70	69
Total Liabilities & Shareholders' Equity	726	808	736	833	664	551	504
Total Liabilities	626	619	620	553	589	536	535
Total Current Liabilities	131	131	136	139	173	121	190
Short-Term Debt	7.30	6.90	6.90	-	-	-	69
Accounts Payable	14	17	20	25	17	26	23
Accrued Expenses	88	86	89	96	140	80	84
Current Deferred Revenue	11	11	10	8.96	6.46	5.38	3.80
Other Current Liabilities	9.96	10	9.90	10	10	10	11
Total Noncurrent Liabilities	495	488	484	414	416	415	345
Long-Term Debt	375	376	376	377	378	378	310
Other Noncurrent Operating Liabilities	106	104	101	32	38	37	35
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	101	189	116	280	74	15	-30
Total Preferred & Common Equity	101	189	116	280	74	15	-30
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	101	189	116	280	74	15	-30
Common Stock	1,049	1,292	1,307	1,319	1,338	1,349	1,357
Retained Earnings	-948	-1,101	-1,186	-1,035	-1,262	-1,332	-1,387
Accumulated Other Comprehensive Income / (Loss)	0.30	-2.18	-3.86	-3.65	-1.89	-1.63	-1.02

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	254.19%	33.74%	15.98%	6.01%	6.75%	13.11%	-33.52%	-16.97%	32.69%	60.55%
EBITDA Growth	-176.40%	239.81%	-129.39%	4.00%	-55.35%	-86.26%	-29.16%	-23.99%	-71.59%	-19.03%	19.04%
EBIT Growth	-207.11%	210.76%	-148.42%	-0.62%	-40.82%	-71.00%	-26.92%	-13.99%	-60.06%	-21.23%	15.37%
NOPAT Growth	-222.16%	-0.98%	27.76%	7.60%	-48.80%	-71.62%	-28.25%	-13.20%	-60.37%	-21.36%	16.57%
Net Income Growth	-220.40%	205.68%	-140.86%	-24.69%	-71.90%	-42.61%	-15.71%	-6.29%	-54.63%	60.00%	-188.64%
EPS Growth	-81.56%	171.56%	-140.69%	-19.38%	-64.94%	-36.22%	-2.89%	15.45%	-45.18%	65.68%	-172.00%
Operating Cash Flow Growth	-160.67%	96.97%	-147.73%	315.14%	-437.13%	-133.25%	26.58%	65.39%	-1,159.40%	-50.31%	15.19%
Free Cash Flow Firm Growth	-1,785.20%	-51.08%	84.89%	191.93%	-421.17%	-9.92%	-139.36%	77.30%	-465.40%	-28.96%	4.10%
Invested Capital Growth	172.62%	508.29%	-15.61%	-60.98%	31.08%	-44.11%	199.14%	-120.38%	28.64%	193.67%	500.29%
Revenue Q/Q Growth	39.90%	19.59%	5.43%	3.23%	0.98%	1.69%	38.80%	-51.60%	18.56%	84.06%	14.61%
EBITDA Q/Q Growth	-0.61%	7.24%	6.77%	4.77%	11.46%	-25.34%	-176.17%	11.18%	-3.67%	2.57%	9.86%
EBIT Q/Q Growth	-8.35%	10.85%	4.65%	2.44%	6.52%	-19.77%	-106.47%	14.41%	-6.82%	2.99%	8.79%
NOPAT Q/Q Growth	-9.53%	-2.62%	-5.47%	5.36%	11.30%	-20.30%	-28.66%	-9.58%	-6.95%	2.85%	9.37%
Net Income Q/Q Growth	-30.99%	29.29%	-14.69%	-17.78%	9.01%	-18.45%	-117.03%	28.00%	-5.39%	-27.97%	8.51%
EPS Q/Q Growth	21.59%	13.21%	-98.46%	-60.42%	8.63%	-17.69%	-109.41%	36.63%	-5.05%	-2.74%	8.11%
Operating Cash Flow Q/Q Growth	-1.55%	79.96%	-329.40%	3,236.86%	-12.19%	-1.62%	-28.11%	-728.68%	-17.51%	-5.99%	12.77%
Free Cash Flow Firm Q/Q Growth	-14.20%	-26.93%	-37.29%	370.47%	-16.76%	7.95%	-58.59%	18.25%	-10.90%	9.22%	5.36%
Invested Capital Q/Q Growth	-46.20%	14.73%	24.20%	-17.51%	21.99%	-33.35%	42.50%	16.55%	48.43%	-48.89%	-4.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	97.98%	97.81%	96.59%	97.67%	96.63%	97.01%	96.91%	97.10%	95.96%	92.12%	96.68%
EBITDA Margin	-336.03%	132.64%	-29.14%	-24.12%	-35.35%	-61.68%	-70.43%	-131.37%	-271.51%	-243.57%	-122.83%
Operating Margin	-282.98%	-50.80%	-43.58%	-34.72%	-48.73%	-78.34%	-88.83%	-151.27%	-292.17%	-267.24%	-138.88%
EBIT Margin	-375.72%	117.49%	-42.54%	-36.90%	-49.02%	-78.52%	-88.11%	-151.09%	-291.28%	-266.15%	-140.30%
Profit (Net Income) Margin	-393.36%	117.36%	-35.86%	-38.55%	-62.51%	-83.51%	-85.43%	-136.60%	-254.41%	-76.70%	-137.90%
Tax Burden Percent	97.83%	111.16%	83.19%	102.34%	100.80%	99.99%	89.75%	83.04%	84.09%	29.62%	100.32%
Interest Burden Percent	107.02%	89.86%	101.34%	102.08%	126.52%	106.37%	108.04%	108.88%	103.86%	97.30%	97.97%
Effective Tax Rate	0.00%	-11.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-84.90%	-38.73%	-56.24%	-129.04%	-250.42%	-224.42%	-425.77%	0.00%	0.00%	-576.89%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-352.41%	-35.13%	-46.79%	-111.25%	-228.69%	-195.82%	-407.68%	0.00%	0.00%	-472.24%
Return on Net Nonoperating Assets (RNNOA)	0.00%	174.14%	22.96%	36.36%	95.45%	196.13%	146.05%	355.60%	0.00%	0.00%	329.44%
Return on Equity (ROE)	389.82%	89.25%	-15.76%	-19.88%	-33.59%	-54.29%	-78.37%	-70.17%	-161.46%	-91.44%	-247.45%
Cash Return on Invested Capital (CROIC)	-535.45%	-228.42%	-21.79%	31.49%	-155.93%	-193.83%	-324.20%	0.00%	0.00%	-2,627.87%	-719.77%
Operating Return on Assets (OROA)	-135.88%	36.24%	-10.95%	-10.94%	-13.10%	-20.96%	-28.83%	-28.78%	-44.00%	-52.90%	-47.31%
Return on Assets (ROA)	-142.26%	36.20%	-9.23%	-11.42%	-16.70%	-22.29%	-27.95%	-26.02%	-38.43%	-15.24%	-46.50%
Return on Common Equity (ROCE)	389.82%	89.25%	-15.76%	-19.88%	-33.59%	-54.29%	-78.37%	-70.17%	-161.46%	-91.44%	-247.45%
Return on Equity Simple (ROE_SIMPLE)	297.81%	39.08%	-15.56%	-20.38%	-32.26%	-66.20%	-80.22%	-59.61%	-649.88%	-55.47%	-544.28%
Net Operating Profit after Tax (NOPAT)	-56	-56	-41	-38	-56	-96	-123	-140	-224	-272	-227
NOPAT Margin	-198.08%	-56.47%	-30.50%	-24.30%	-34.11%	-54.84%	-62.18%	-105.89%	-204.52%	-187.07%	-97.21%
Net Nonoperating Expense Percent (NNEP)	220.98%	267.51%	-3.60%	-9.45%	-17.79%	-21.73%	-28.60%	-18.09%	-29.23%	131.17%	-104.65%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-53.51%	-47.00%	-51.75%
Cost of Revenue to Revenue	2.02%	2.19%	3.41%	2.33%	3.37%	2.99%	3.09%	2.90%	4.04%	7.88%	3.32%
SG&A Expenses to Revenue	211.48%	79.63%	68.82%	65.40%	63.11%	73.54%	68.47%	95.79%	180.45%	182.83%	113.27%
R&D to Revenue	169.47%	50.48%	53.01%	50.45%	75.35%	80.40%	115.42%	152.58%	207.69%	168.68%	121.24%
Operating Expenses to Revenue	380.95%	148.62%	140.17%	132.39%	145.37%	175.36%	185.74%	248.37%	388.14%	359.36%	235.56%
Earnings before Interest and Taxes (EBIT)	-106	117	-57	-57	-81	-138	-175	-199	-319	-387	-327
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-95	132	-39	-37	-58	-108	-140	-173	-297	-354	-286
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.32	2.32	2.83	2.93	2.76	6.59	6.29	31.49	3.36	23.01
Price to Tangible Book Value (P/TBV)	0.00	5.07	5.72	7.71	7.15	9.67	24.37	12.37	0.00	7.01	0.00
Price to Revenue (P/Rev)	11.59	6.98	5.35	5.35	5.68	3.48	7.02	14.42	12.33	4.65	5.83
Price to Earnings (P/E)	0.00	5.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	16.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20.40	4.48	5.22	15.24	13.49	15.12	15.33	0.00	0.00	43.31	20.31
Enterprise Value to Revenue (EV/Rev)	13.57	5.12	3.76	3.70	4.05	2.37	6.37	12.00	11.65	3.35	5.87
Enterprise Value to EBITDA (EV/EBITDA)	0.00	3.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	4.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	77.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	27.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-2.25	0.15	0.14	0.15	0.68	0.93	1.10	0.77	8.76	1.88	6.42
Long-Term Debt to Equity	-1.16	0.15	0.14	0.15	0.61	0.93	1.02	0.75	8.76	1.88	5.25
Financial Leverage	-0.88	-0.49	-0.65	-0.78	-0.86	-0.86	-0.75	-0.87	-1.08	-1.00	-0.70
Leverage Ratio	-2.74	2.47	1.71	1.74	2.01	2.44	2.80	2.70	4.20	6.00	5.32
Compound Leverage Factor	-2.93	2.22	1.73	1.78	2.54	2.59	3.03	2.94	4.36	5.84	5.21
Debt to Total Capital	180.07%	12.73%	12.61%	13.33%	40.60%	48.08%	52.42%	43.65%	89.76%	65.26%	86.51%
Short-Term Debt to Total Capital	87.02%	0.00%	0.00%	0.00%	4.19%	0.00%	3.92%	1.38%	0.00%	0.00%	15.68%
Long-Term Debt to Total Capital	93.05%	12.73%	12.61%	13.33%	36.41%	48.08%	48.51%	42.27%	89.76%	65.26%	70.84%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-80.07%	87.27%	87.39%	86.67%	59.40%	51.92%	47.58%	56.35%	10.24%	34.74%	13.49%
Debt to EBITDA	-0.88	0.33	-1.14	-1.21	-3.75	-1.89	-1.67	-1.35	-1.26	-1.07	-1.32
Net Debt to EBITDA	-0.59	-1.40	5.43	6.84	4.63	1.79	0.92	1.84	0.25	0.54	-0.03
Long-Term Debt to EBITDA	-0.46	0.33	-1.14	-1.21	-3.36	-1.89	-1.54	-1.31	-1.26	-1.07	-1.08
Debt to NOPAT	-1.50	-0.78	-1.09	-1.20	-3.88	-2.13	-1.89	-1.68	-1.68	-1.39	-1.67
Net Debt to NOPAT	-1.00	3.29	5.19	6.79	4.80	2.01	1.04	2.28	0.33	0.70	-0.04
Long-Term Debt to NOPAT	-0.77	-0.78	-1.09	-1.20	-3.48	-2.13	-1.75	-1.62	-1.68	-1.39	-1.37
Altman Z-Score	-3.71	3.25	2.14	2.20	1.42	0.19	0.76	1.05	-1.61	-2.07	-2.87
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.35	3.47	3.99	3.80	4.74	4.50	4.43	4.70	3.42	3.47	2.08
Quick Ratio	0.33	3.32	3.86	3.67	4.63	4.36	4.07	4.58	3.28	3.31	1.98
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-100	-152	-23	21	-68	-74	-178	-40	-229	-295	-283
Operating Cash Flow to CapEx	-6,915.54%	0.00%	-240.97%	834.61%	-3,433.01%	-29,853.33%	-631.64%	-289.98%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-36.57	-31.63	4.77	-2.52	0.00	0.00	0.00	-12.30	-26.02	-25.29
Operating Cash Flow to Interest Expense	0.00	-0.33	-4.75	1.67	-0.93	0.00	0.00	0.00	-10.02	-24.71	-21.24
Operating Cash Flow Less CapEx to Interest Expense	0.00	35.41	-6.72	1.47	-0.96	0.00	0.00	0.00	-10.02	-24.71	-21.24
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.31	0.26	0.30	0.27	0.27	0.33	0.19	0.15	0.20	0.34
Accounts Receivable Turnover	0.00	9.78	8.63	9.57	12.38	11.42	11.68	8.28	6.72	7.68	9.66
Inventory Turnover	0.00	1.31	1.70	0.88	1.01	0.89	0.90	0.51	0.75	1.64	0.99
Fixed Asset Turnover	70.65	181.79	88.62	53.27	51.52	58.09	32.22	12.85	10.86	17.57	36.39
Accounts Payable Turnover	0.11	0.30	0.60	0.27	0.43	0.31	0.32	0.28	0.27	0.39	0.24
Days Sales Outstanding (DSO)	0.00	37.30	42.31	38.14	29.48	31.96	31.26	44.07	54.29	47.53	37.80
Days Inventory Outstanding (DIO)	0.00	278.72	214.88	413.95	362.23	407.99	407.84	713.22	488.70	222.08	367.88
Days Payable Outstanding (DPO)	3,412.71	1,233.07	607.57	1,339.51	854.95	1,170.45	1,154.31	1,303.84	1,339.19	939.84	1,536.76
Cash Conversion Cycle (CCC)	-3,412.71	-917.04	-350.39	-887.42	-463.24	-730.50	-715.21	-546.54	-796.20	-670.23	-1,131.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	19	114	96	38	49	28	82	-17	-12	11	67
Invested Capital Turnover	-7.97	1.50	1.27	2.31	3.78	4.57	3.61	4.02	-7.61	-382.71	5.93
Increase / (Decrease) in Invested Capital	45	95	-18	-59	12	-22	55	-99	4.81	23	56
Enterprise Value (EV)	383	511	503	573	664	416	1,263	1,582	1,275	486	1,368
Market Capitalization	327	697	714	828	933	610	1,391	1,900	1,350	676	1,360
Book Value per Share	($1.40)	$8.30	$8.16	$7.46	$7.72	$5.15	$4.14	$4.93	$0.67	$2.67	$0.76
Tangible Book Value per Share	($4.96)	$3.80	$3.31	$2.73	$3.17	$1.47	$1.12	$2.51	($0.84)	$1.28	($0.58)
Total Capital	47	344	352	338	536	426	444	536	418	578	438
Total Debt	84	44	44	45	218	205	233	234	376	377	379
Total Long-Term Debt	43	44	44	45	195	205	215	227	376	377	310
Net Debt	56	-186	-211	-256	-269	-194	-129	-319	-75	-190	8.29
Capital Expenditures (CapEx)	0.66	-148	1.43	0.89	0.73	0.20	6.77	5.10	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-57	-15	-6.78	-60	-58	-65	-26	-87	-106	-128	-86
Debt-free Net Working Capital (DFNWC)	-30	215	249	240	414	334	335	466	344	439	285
Net Working Capital (NWC)	-70	215	249	240	391	334	318	459	344	439	216
Net Nonoperating Expense (NNE)	55	-174	7.15	22	47	50	46	40	55	-160	95
Net Nonoperating Obligations (NNO)	56	-186	-211	-256	-269	-194	-129	-319	-55	-190	8.29
Total Depreciation and Amortization (D&A)	11	15	18	20	22	30	35	26	22	33	41
Debt-free, Cash-free Net Working Capital to Revenue	-203.80%	-14.67%	-5.08%	-39.04%	-35.33%	-37.02%	-13.33%	-65.80%	-96.81%	-88.12%	-36.91%
Debt-free Net Working Capital to Revenue	-105.38%	215.18%	186.46%	154.99%	251.77%	190.27%	168.99%	353.57%	314.52%	302.17%	122.07%
Net Working Capital to Revenue	-248.93%	215.18%	186.46%	154.99%	238.09%	190.27%	160.22%	347.96%	314.52%	302.17%	92.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.43)	$3.49	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)
Adjusted Weighted Average Basic Shares Outstanding	26.49M	33.56M	37.00M	38.77M	40.43M	43.12M	60.24M	59.83M	63.76M	74.27M	78.89M
Adjusted Diluted Earnings per Share	($4.43)	$3.17	($1.29)	($1.54)	($2.54)	($3.46)	($3.56)	($3.01)	($4.37)	($1.50)	($4.08)
Adjusted Weighted Average Diluted Shares Outstanding	26.49M	37.58M	38.29M	38.77M	40.43M	43.12M	60.24M	59.83M	63.76M	74.27M	78.89M
Adjusted Basic & Diluted Earnings per Share	($4.43)	$0.00	$0.00	$0.00	($2.54)	($3.46)	($3.56)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.06M	36.51M	38.09M	39.69M	41.41M	42.34M	47.54M	63.21M	64.74M	76.10M	88.74M
Normalized Net Operating Profit after Tax (NOPAT)	-56	-23	-24	-33	-56	-68	-123	-140	-224	-264	-225
Normalized NOPAT Margin	-198.08%	-22.61%	-17.67%	-21.49%	-34.22%	-38.67%	-62.18%	-105.89%	-204.52%	-181.58%	-96.48%
Pre Tax Income Margin	-402.08%	105.58%	-43.10%	-37.67%	-62.02%	-83.52%	-95.19%	-164.51%	-302.54%	-258.96%	-137.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	28.27	-78.38	-12.93	-3.00	0.00	0.00	0.00	-17.15	-34.10	-29.26
NOPAT to Interest Expense	0.00	-13.59	-56.21	-8.52	-2.09	0.00	0.00	0.00	-12.04	-23.97	-20.27
EBIT Less CapEx to Interest Expense	0.00	64.02	-80.35	-13.13	-3.03	0.00	0.00	0.00	-17.15	-34.10	-29.26
NOPAT Less CapEx to Interest Expense	0.00	22.16	-58.18	-8.72	-2.11	0.00	0.00	0.00	-12.04	-23.97	-20.27
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-4.89%	8.10%	0.00%	0.00%	-8.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-58.84%	44.62%	-36.30%	-40.56%	32.13%	311.85%	33.95%	68.08%	69.56%	65.98%
EBITDA Growth	-315.50%	-12.05%	-53.63%	-64.44%	4.47%	14.79%	-42.42%	34.71%	45.04%	40.96%
EBIT Growth	-167.86%	-24.12%	-47.17%	-60.76%	-10.89%	11.36%	-42.88%	31.64%	39.70%	33.97%
NOPAT Growth	-160.49%	-24.49%	-47.24%	-58.82%	-12.08%	10.79%	-43.00%	34.87%	39.35%	35.55%
Net Income Growth	-95.45%	-27.63%	-13.64%	-27.75%	316.40%	-36.99%	-57.60%	17.78%	-136.36%	33.17%
EPS Growth	-84.75%	-25.61%	-5.83%	-7.62%	280.73%	-3.88%	-38.58%	19.47%	-135.53%	33.64%
Operating Cash Flow Growth	-223.27%	-103.30%	-46.63%	-88.28%	-49.61%	-28.98%	-46.71%	41.93%	28.12%	49.31%
Free Cash Flow Firm Growth	-198.19%	-298.07%	-440.78%	-9,747.35%	-101.07%	-13.23%	-6.09%	-11.63%	19.99%	-10.65%
Invested Capital Growth	-15.48%	28.64%	178.27%	158.40%	194.50%	193.67%	2.09%	703.17%	221.84%	500.29%
Revenue Q/Q Growth	-48.17%	-175.76%	245.23%	4.23%	15.22%	21.47%	-8.18%	30.80%	16.23%	18.90%
EBITDA Q/Q Growth	-49.18%	-15.72%	7.34%	-2.80%	13.34%	-3.22%	-53.84%	52.87%	27.05%	-10.90%
EBIT Q/Q Growth	-28.40%	-25.92%	7.13%	-7.06%	11.43%	-0.66%	-49.69%	48.78%	21.87%	-10.23%
NOPAT Q/Q Growth	-26.21%	-27.87%	7.82%	-6.76%	10.93%	-1.78%	-47.76%	51.38%	17.07%	-8.17%
Net Income Q/Q Growth	-3.91%	5.50%	-31.16%	0.81%	276.03%	-159.82%	-50.89%	48.25%	22.15%	-9.95%
EPS Q/Q Growth	-3.81%	5.50%	-23.30%	11.02%	274.34%	-154.31%	-64.49%	48.30%	23.08%	-1.43%
Operating Cash Flow Q/Q Growth	-7.39%	-38.24%	-48.46%	14.57%	14.67%	-19.18%	-68.87%	66.18%	-5.63%	15.97%
Free Cash Flow Firm Q/Q Growth	-5,530.11%	-43.94%	-16.92%	-3.92%	-14.96%	18.94%	-9.55%	-9.35%	17.61%	-12.10%
Invested Capital Q/Q Growth	-60.56%	48.43%	187.65%	-19.52%	159.80%	-48.89%	-4.47%	533.17%	4.11%	-4.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	96.03%	0.00%	86.58%	95.49%	96.53%	89.87%	96.36%	96.19%	97.41%	96.59%
EBITDA Margin	-301.18%	0.00%	-293.52%	-289.49%	-217.75%	-185.03%	-312.08%	-112.45%	-70.57%	-65.82%
Operating Margin	-294.23%	0.00%	-315.23%	-322.87%	-249.59%	-209.13%	-336.53%	-125.11%	-89.27%	-81.21%
EBIT Margin	-296.31%	0.00%	-314.95%	-323.49%	-248.69%	-206.09%	-335.96%	-131.57%	-88.44%	-81.99%
Profit (Net Income) Margin	-248.11%	0.00%	-279.50%	-265.96%	406.35%	-200.12%	-328.86%	-130.11%	-87.14%	-80.58%
Tax Burden Percent	83.00%	63.09%	89.48%	84.06%	-168.93%	101.86%	100.22%	101.21%	99.95%	99.87%
Interest Burden Percent	100.88%	99.60%	99.18%	97.81%	96.73%	95.33%	97.67%	97.71%	98.57%	98.41%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,457.36%	-407.65%	-274.53%	-337.36%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,425.46%	-324.42%	-254.73%	-317.78%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,149.29%	136.30%	160.10%	221.69%
Return on Equity (ROE)	-129.51%	-161.46%	-145.41%	-225.07%	-45.76%	-91.44%	-308.07%	-271.35%	-114.43%	-115.67%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-2,567.88%	-3,497.90%	-1,479.61%	-2,627.87%	-2,838.92%	-877.95%	-645.30%	-719.77%
Operating Return on Assets (OROA)	-36.44%	0.00%	-35.36%	-29.83%	-25.17%	-40.96%	-71.09%	-36.30%	-26.91%	-27.65%
Return on Assets (ROA)	-30.52%	0.00%	-31.38%	-24.52%	41.13%	-39.77%	-69.59%	-35.90%	-26.52%	-27.17%
Return on Common Equity (ROCE)	-129.51%	-161.46%	-145.41%	-225.07%	-45.76%	-91.44%	-308.07%	-271.35%	-114.43%	-115.67%
Return on Equity Simple (ROE_SIMPLE)	-262.46%	0.00%	-152.71%	-263.93%	-31.11%	0.00%	-217.53%	-963.28%	1,154.05%	0.00%
Net Operating Profit after Tax (NOPAT)	-58	-74	-68	-73	-65	-66	-97	-47	-39	-43
NOPAT Margin	-205.96%	0.00%	-220.66%	-226.01%	-174.71%	-146.39%	-235.57%	-87.58%	-62.49%	-56.85%
Net Nonoperating Expense Percent (NNEP)	-5.24%	4.34%	-9.08%	-9.21%	112.93%	-19.81%	-31.90%	-83.23%	-19.79%	-19.58%
Return On Investment Capital (ROIC_SIMPLE)	-	-17.67%	-	-	-	-11.41%	-	-	-	-9.71%
Cost of Revenue to Revenue	3.97%	0.00%	13.42%	4.51%	3.47%	10.13%	3.64%	3.81%	2.59%	3.41%
SG&A Expenses to Revenue	186.71%	0.00%	213.51%	211.84%	182.78%	141.12%	155.23%	119.70%	104.33%	92.93%
R&D to Revenue	203.54%	0.00%	188.30%	206.52%	163.34%	132.60%	277.05%	100.40%	82.16%	82.99%
Operating Expenses to Revenue	390.26%	0.00%	401.81%	418.36%	346.11%	299.00%	432.90%	221.30%	186.68%	177.80%
Earnings before Interest and Taxes (EBIT)	-83	-105	-97	-104	-92	-93	-139	-71	-56	-61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-85	-98	-91	-93	-81	-83	-129	-61	-44	-49
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	15.65	31.49	7.70	9.84	2.40	3.36	7.82	41.31	0.00	23.01
Price to Tangible Book Value (P/TBV)	0.00	0.00	55.46	0.00	3.88	7.01	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	17.07	12.33	15.85	16.40	8.50	4.65	3.72	3.52	5.26	5.83
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	121.65	122.82	18.80	43.31	48.14	10.00	16.57	20.31
Enterprise Value to Revenue (EV/Rev)	15.73	11.65	13.91	14.85	5.23	3.35	3.31	3.82	5.76	5.87
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.80	8.76	2.02	3.29	1.35	1.88	5.10	24.96	-12.43	6.42
Long-Term Debt to Equity	3.73	8.76	1.99	3.23	1.35	1.88	5.10	24.96	-10.18	5.25
Financial Leverage	-1.11	-1.08	-1.01	-1.02	-1.00	-1.00	-0.92	-0.42	-0.63	-0.70
Leverage Ratio	3.68	4.20	4.12	5.55	4.10	6.00	5.59	9.78	5.36	5.32
Compound Leverage Factor	3.71	4.18	4.09	5.43	3.96	5.72	5.46	9.56	5.29	5.24
Debt to Total Capital	79.16%	89.76%	66.93%	76.69%	57.39%	65.26%	83.60%	96.15%	108.75%	86.51%
Short-Term Debt to Total Capital	1.51%	0.00%	1.21%	1.38%	0.00%	0.00%	0.00%	0.00%	19.71%	15.68%
Long-Term Debt to Total Capital	77.65%	89.76%	65.73%	75.31%	57.39%	65.26%	83.60%	96.15%	89.04%	70.84%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	20.84%	10.24%	33.07%	23.31%	42.61%	34.74%	16.40%	3.85%	-8.75%	13.49%
Debt to EBITDA	-1.33	-1.26	-1.16	-1.05	-1.04	-1.07	-0.98	-1.07	-1.19	-1.32
Net Debt to EBITDA	0.43	0.25	0.54	0.29	0.71	0.54	0.16	-0.15	-0.32	-0.03
Long-Term Debt to EBITDA	-1.31	-1.26	-1.14	-1.03	-1.04	-1.07	-0.98	-1.07	-0.98	-1.08
Debt to NOPAT	-1.83	-1.68	-1.56	-1.41	-1.35	-1.39	-1.25	-1.37	-1.51	-1.67
Net Debt to NOPAT	0.59	0.33	0.73	0.40	0.92	0.70	0.21	-0.19	-0.40	-0.04
Long-Term Debt to NOPAT	-1.79	-1.68	-1.53	-1.38	-1.35	-1.39	-1.25	-1.37	-1.24	-1.37
Altman Z-Score	0.10	-0.56	-0.07	-0.86	-0.50	-0.85	-1.97	-2.25	-2.29	-1.40
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.08	3.42	4.63	3.99	4.92	3.47	2.78	3.04	1.71	2.08
Quick Ratio	3.96	3.28	4.46	3.77	4.66	3.31	2.68	2.89	1.59	1.98
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-55	-79	-92	-96	-110	-89	-98	-107	-88	-99
Operating Cash Flow to CapEx	0.00%	0.00%	-12,875.71%	-2,309,900.00%	-591,340.00%	0.00%	0.00%	-49,076.83%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-7.15	0.00	-33.66	-38.99	0.00	0.00	-38.31	-31.69	0.00
Operating Cash Flow to Interest Expense	0.00	-4.96	0.00	-24.37	-20.96	0.00	0.00	-14.43	-15.31	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-4.96	0.00	-24.38	-20.97	0.00	0.00	-14.46	-15.31	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.12	0.15	0.11	0.09	0.10	0.20	0.21	0.28	0.30	0.34
Accounts Receivable Turnover	7.09	6.72	5.07	3.77	5.79	7.68	7.04	7.92	10.24	9.66
Inventory Turnover	0.61	0.75	0.97	0.44	0.43	1.64	1.57	0.76	0.72	0.99
Fixed Asset Turnover	8.76	10.86	9.31	7.49	8.99	17.57	19.38	23.45	28.74	36.39
Accounts Payable Turnover	0.43	0.27	0.37	0.37	0.31	0.39	0.53	0.41	0.41	0.24
Days Sales Outstanding (DSO)	51.47	54.29	71.94	96.84	63.00	47.53	51.88	46.09	35.65	37.80
Days Inventory Outstanding (DIO)	599.84	488.70	375.76	826.60	853.37	222.08	232.95	479.43	507.54	367.88
Days Payable Outstanding (DPO)	855.37	1,339.19	998.43	994.64	1,177.94	939.84	693.04	886.69	896.71	1,536.76
Cash Conversion Cycle (CCC)	-204.06	-796.20	-550.72	-71.19	-261.57	-670.23	-408.21	-361.17	-353.52	-1,131.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-23	-12	11	8.45	22	11	11	68	71	67
Invested Capital Turnover	-4.26	-7.61	-63.03	-23.22	-123.59	-382.71	14.68	4.65	4.39	5.93
Increase / (Decrease) in Invested Capital	-3.12	4.81	24	23	45	23	0.22	59	49	56
Enterprise Value (EV)	1,452	1,275	1,277	1,038	413	486	516	679	1,171	1,368
Market Capitalization	1,576	1,350	1,456	1,146	671	676	579	626	1,070	1,360
Book Value per Share	$1.57	$0.67	$2.92	$1.56	$3.73	$2.67	$0.96	$0.20	($0.40)	$0.76
Tangible Book Value per Share	($0.76)	($0.84)	$0.41	($0.51)	$2.30	$1.28	($0.35)	($1.18)	($1.76)	($0.58)
Total Capital	483	418	572	500	657	578	452	393	348	438
Total Debt	382	376	383	383	377	377	378	378	379	379
Total Long-Term Debt	375	376	376	376	377	377	378	378	310	310
Net Debt	-124	-75	-179	-108	-258	-190	-63	53	101	8.29
Capital Expenditures (CapEx)	0.00	0.00	0.63	0.00	0.01	0.00	0.00	0.08	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-95	-106	-80	-78	-88	-128	-133	-78	-74	-86
Debt-free Net Working Capital (DFNWC)	411	344	481	413	547	439	308	248	203	285
Net Working Capital (NWC)	404	344	474	406	547	439	308	248	135	216
Net Nonoperating Expense (NNE)	12	-8.12	18	13	-216	24	39	23	16	18
Net Nonoperating Obligations (NNO)	-124	-55	-179	-108	-258	-190	-63	53	101	8.29
Total Depreciation and Amortization (D&A)	-1.37	6.91	6.62	11	11	9.49	9.88	10	11	12
Debt-free, Cash-free Net Working Capital to Revenue	-103.13%	-96.81%	-87.47%	-111.74%	-111.32%	-88.12%	-85.53%	-43.73%	-36.44%	-36.91%
Debt-free Net Working Capital to Revenue	445.29%	314.52%	523.79%	591.28%	692.94%	302.17%	197.69%	139.44%	99.93%	122.07%
Net Working Capital to Revenue	437.38%	314.52%	516.28%	581.41%	692.94%	302.17%	197.69%	139.44%	66.21%	92.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.09)	($1.03)	($1.27)	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)
Adjusted Weighted Average Basic Shares Outstanding	64.03M	63.76M	68.17M	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M
Adjusted Diluted Earnings per Share	($1.09)	($1.03)	($1.27)	($1.13)	$1.97	($1.07)	($1.76)	($0.91)	($0.70)	($0.71)
Adjusted Weighted Average Diluted Shares Outstanding	64.03M	63.76M	68.17M	76.00M	76.31M	74.27M	77.14M	77.50M	77.78M	78.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	64.17M	64.74M	74.61M	75.01M	75.15M	76.10M	76.13M	76.49M	78.05M	88.74M
Normalized Net Operating Profit after Tax (NOPAT)	-58	-74	-68	-73	-65	-58	-97	-47	-39	-42
Normalized NOPAT Margin	-205.96%	0.00%	-220.66%	-226.01%	-174.71%	-128.69%	-235.13%	-86.73%	-62.35%	-55.54%
Pre Tax Income Margin	-298.91%	0.00%	-312.37%	-316.40%	-240.54%	-196.47%	-328.15%	-128.55%	-87.18%	-80.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-9.51	0.00	-36.63	-32.70	0.00	0.00	-25.54	-20.03	0.00
NOPAT to Interest Expense	0.00	-6.71	0.00	-25.59	-22.97	0.00	0.00	-17.00	-14.15	0.00
EBIT Less CapEx to Interest Expense	0.00	-9.51	0.00	-36.64	-32.70	0.00	0.00	-25.57	-20.03	0.00
NOPAT Less CapEx to Interest Expense	0.00	-6.71	0.00	-25.60	-22.98	0.00	0.00	-17.03	-14.15	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Travere Therapeutics' Financials

When does Travere Therapeutics's financial year end?

According to the most recent income statement we have on file, Travere Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Travere Therapeutics' net income changed over the last 10 years?

Travere Therapeutics' net income appears to be on an upward trend, with a most recent value of -$321.55 million in 2024, rising from -$110.94 million in 2014. The previous period was -$111.40 million in 2023. Check out Travere Therapeutics' forecast to explore projected trends and price targets.

What is Travere Therapeutics's operating income?

Travere Therapeutics's total operating income in 2024 was -$323.83 million, based on the following breakdown:

Total Gross Profit: $225.43 million
Total Operating Expenses: $549.26 million

How has Travere Therapeutics revenue changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' total revenue changed from $28.20 million in 2014 to $233.18 million in 2024, a change of 726.8%.

How much debt does Travere Therapeutics have?

Travere Therapeutics' total liabilities were at $535.05 million at the end of 2024, a 9.0% decrease from 2023, and a 209.8% increase since 2014.

How much cash does Travere Therapeutics have?

In the past 10 years, Travere Therapeutics' cash and equivalents has ranged from $18.20 million in 2014 to $165.75 million in 2021, and is currently $58.54 million as of their latest financial filing in 2024.

How has Travere Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' book value per share changed from -1.40 in 2014 to 0.76 in 2024, a change of -154.3%.

Related Companies

This page (NASDAQ:TVTX) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Financials

Frequently Asked Questions About Travere Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Financials

Annual Income Statements for Travere Therapeutics

Quarterly Income Statements for Travere Therapeutics

Annual Cash Flow Statements for Travere Therapeutics

Quarterly Cash Flow Statements for Travere Therapeutics

Annual Balance Sheets for Travere Therapeutics

Quarterly Balance Sheets for Travere Therapeutics

Annual Metrics and Ratios for Travere Therapeutics

Quarterly Metrics and Ratios for Travere Therapeutics

Frequently Asked Questions About Travere Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools